Most Read Articles
Pearl Toh, 31 Dec 2019
Adding the neuraminidase inhibitor oseltamivir to usual care speeds up recovery from influenza-like illness by a day compared with usual care alone, with even greater benefits seen in older, sicker patients with comorbidities, according to the ALIC4E study.
Roshini Claire Anthony, 03 Feb 2020

The emergence of a novel coronavirus (preliminarily referred to as 2019-nCoV) has taken hold of public attention in the last month. MIMS Doctor speaks to Professor Dale Fisher, a senior consultant at the Division of Infectious Diseases, National University Hospital, Singapore, to get a better picture of the situation and steps being undertaken in Singapore to prevent spread of the virus.

Pearl Toh, 04 Feb 2020
Four months of daily rifampicin is safer than 9 months of daily isoniazid when it comes to treating latent tuberculosis (TB) infection, according to a post hoc safety analysis on pooled data from two randomized studies* — thus rendering the ambitious goal by the WHO to treat 30 million patients possible.
Jairia Dela Cruz, 31 Jan 2020
A week-long course of the centrally acting neurokinin-1 inhibitor aprepitant for treating cough in advanced lung cancer patients is effective and safe, producing significant improvements in cough severity and impact without increasing severe side effects, according to the results of a trial.

Age, lung V20 predict radiation pneumonitis

Jackey Suen
16 Oct 2018

Age ≥60 years and ≥20 percent of normal lung volume receiving a radiation dose of ≥20 Gy (V20) are significant predictors of radiation pneumonitis (RP) in patients treated with intensity-modulated radiotherapy (IMRT) for lung cancer, a Chinese study has shown.

“The study aimed to correlate clinical and dosimetric factors with the development of RP in patients with lung cancer treated with IMRT,” noted researchers from the PLA General Hospital, Beijing, China, at the International Association for the Study of Lung Cancer (IASLC) 19th World Conference on Lung Cancer (WCLC 2018).

The study included 149 patients with lung cancer (squamous cell carcinoma, 30.2 percent; adenocarcinoma, 18.8 percent; small cell lung cancer, 38.2 percent; others, 12.8 percent). Most patients had stage III (65.1 percent) or IV disease (28.2 percent). Potential predictive factors for RP investigated in the study included age, gender, histology, tumour stage, pulmonary function, Karnofsky performance score, radiation dose, surgery history, and chemotherapy use. [Du L, et al, WCLC 2018, abstract P1.17-19]

After a median follow-up of 9 months, 62.7 percent, 38.3 percent, and 6.7 percent of the patients developed grade ≤1, grade ≥2, and grade ≥3 RP, respectively.

In multivariate analysis, age ≥60 years (age ≥60 years vs <60 years, adjusted hazard ratio [aHR], 2.517; 95 percent confidence interval [CI], 1.167 to 5.430; p=0.019) and V20 ≥20 percent (V20 ≥20 to <25 percent vs <20 percent, aHR, 2.971; 95 percent CI, 1.085 to 8.133; p=0.034; V20 ≥25 percent vs <20 percent, aHR, 5.810; 95 percent CI, 1.391 to 24.27; p=0.016) were significant predictors of grade ≥2 RP. Patients with a history of surgery were also more prone to grade ≥2 RP, but the predictive value reached only borderline significance (vs no surgery, aHR, 3.048; 95 percent CI, 0.959 to 9.686; p=0.059). Other potential factors failed to demonstrate statistical significance.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Respirology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 31 Dec 2019
Adding the neuraminidase inhibitor oseltamivir to usual care speeds up recovery from influenza-like illness by a day compared with usual care alone, with even greater benefits seen in older, sicker patients with comorbidities, according to the ALIC4E study.
Roshini Claire Anthony, 03 Feb 2020

The emergence of a novel coronavirus (preliminarily referred to as 2019-nCoV) has taken hold of public attention in the last month. MIMS Doctor speaks to Professor Dale Fisher, a senior consultant at the Division of Infectious Diseases, National University Hospital, Singapore, to get a better picture of the situation and steps being undertaken in Singapore to prevent spread of the virus.

Pearl Toh, 04 Feb 2020
Four months of daily rifampicin is safer than 9 months of daily isoniazid when it comes to treating latent tuberculosis (TB) infection, according to a post hoc safety analysis on pooled data from two randomized studies* — thus rendering the ambitious goal by the WHO to treat 30 million patients possible.
Jairia Dela Cruz, 31 Jan 2020
A week-long course of the centrally acting neurokinin-1 inhibitor aprepitant for treating cough in advanced lung cancer patients is effective and safe, producing significant improvements in cough severity and impact without increasing severe side effects, according to the results of a trial.